Extreme Investor Network

FDA Approves Merck’s RSV Vaccine for Infants to Compete with Sanofi-AstraZeneca

June 10, 2025

These stocks are a good buy amid tariff uncertainty, according to investor

Merck’s Enflonsia: A New Hope Against RSV In a significant advancement for infant healthcare, the Food and Drug Administration (FDA) has granted approval for Merck’s Enflonsia, a monoclonal antibody treatment designed to protect infants from … Read more

Trial Shows Merck’s Experimental RSV Treatment Protects Infants

October 17, 2024

Merck says experimental RSV treatment protected infants in trial

When it comes to protecting infants from respiratory syncytial virus (RSV), pharmaceutical giant Merck is making headlines with positive results from its recent trial of an experimental treatment called clesrovimab. This new treatment has the … Read more